Elaine Sorg
Vermogen: - $ op 30-06-2026
Vermogen: - $ op 30-06-2026
Elaine K.
Sorg is Director at Artiva Biotherapeutics, Inc. since 2026.
Ms. Sorg is Independent Non-Executive Director at CSL Ltd. since 2024.
Ms. Sorg was Senior VP & President-US Commercial Operations at AbbVie, Inc. from 2020 to 2024.
Ms. Sorg completed graduate studies at Harvard Business School and the University of Chicago Booth School of Business.
Ms. Sorg completed undergraduate studies at Purdue University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2026 | 0 ( -.--% ) | - $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| CSL LIMITED | Directeur/Bestuurslid | 01-09-2024 |
| ARTIVA BIOTHERAPEUTICS, INC. | Directeur/Bestuurslid | 19-02-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
| ABBVIE INC. | Corporate Officer/Principal | 01-01-2024 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
CSL Ltd.
CSL Ltd. BiotechnologyHealth Technology Develops and manufactures medicines that treat people with rare and serious diseases | Health Technology |
AbbVie, Inc.
AbbVie, Inc. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufacturing, commercialization & sale of immunology medicines and therapies | Health Technology |
Purdue University
Purdue University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops natural killer cell-based therapies for patients suffering from autoimmune diseases and cancers | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau